API | aramchol

aramchol Report issue

Small molecule Experimental

AACT DrugBank MeSH PubChem

Active Ingredient History

NOW

Aramchol is an investigational drug being developed by Galmed Pharmaceuticals as a first-in-class, potentially disease modifying treatment for nonalcoholic steatohepatitis, or NASH, a more advanced condition of non-alcoholic fatty liver disease. ^Wikipedia

Chemistry

SMILES: Missing data
InChIKey: Missing data
Mol. Mass: Missing data
ALogP: Missing data
ChEMBL Molecules: Missing data

More Chemistry

Pharmacology

Mechanism of Action:
- Acyl-CoA desaturase (Homo sapiens) ^UniProt
Multi-specific: Missing data
Black Box: Missing data
Availability: Missing data
Delivery Methods: Missing data
Pro Drug: Missing data

arachidyl amido cholanoic acid | aramchol

Organizations (23)

Research & Development (23)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (0)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (7)

Approved Indications (1)

Non-alcoholic Fatty Liver Disease

Experimental Indications - Clinical Trial Phases 1-4 (7)

Fatty Liver (Phase 2/Phase 3)

Gallstones (Phase 2)

Healthy Volunteers (Phase 1)

HIV (Phase 2)

Liver Diseases (Phase 2/Phase 3)

Metabolic Syndrome (Phase 2)

Non-alcoholic Fatty Liver Disease (Phase 3)

Overview

Highest Phase: Phase 3
# of Trials: 11
# of Trial Organizations: 23

Trials by Phase

Trial	Phase	Start Date	Organizations	Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue